REVOFIL™ ULTRA

Key Uses of Revofil Ultra

• Facial contouring in areas such as the chin, cheeks, jawline, and temples

• Deep wrinkle correction, particularly for marionette lines and nasolabial folds

• Lip augmentation and enhancement for increased fullness

• Volume restoration in the mid-face area, especially for age-related volume loss

• Treatment of the nose bridge and forehead region

• Enhancement of skin elasticity and hydration

• Tear trough treatment

• Fine line correction

• Temporal region enhancement

Manufacturing Information for Revofil Ultra

Revofil Ultra is produced by Caregen Co., Ltd., a South Korean company recognized for their expertise in aesthetic solutions.  Caregen Co. specializes in developing dermal fillers, including the complete Revofil product range. Their manufacturing process incorporates advanced cross-linking technology and precision formulation of key ingredients.

Expected Benefits and Results of the Treatment

• Improved facial contours and enhanced volume distribution

• Significant reduction in deep wrinkles and fine lines

• Enhanced skin elasticity and stability

• Natural-looking results that maintain facial expressiveness

• Long-lasting effects up to 12 months

• Smooth application and even distribution

• Progressive improvement through advanced peptide technology

• Immediate volume restoration with continued enhancement over time

Revofil Ultra Key Ingredients and Device Features

The dermal fillers product incorporates hyaluronic acid at a concentration of 23 mg/ml as its primary active ingredient. 

The formula features two specialized biometric peptides: 

1. Oligopeptide-50 (CG-Glamerin), which provides anti-inflammatory benefits and promotes collagen and elastin production, and 
2. Oligopeptide-72 (CG-Boostrin), works to prevent hyaluronic acid degradation for consistent absorption. 

Revofil Ultra is characterized as a biodegradable dermal filler of non-animal origin, utilizing advanced cross-linked technology for enhanced stability.

Included Items or Accessories

Each Revofil Ultra package contains:

• 1 pre-filled syringes (1ml each)
• 2 sterile 27G needles

Administration Method for Revofil Ultra

The administration of Revofil Ultra must be performed by qualified medical professionals following specific protocols. The process begins with a thorough cleansing of the treatment area to maintain aseptic conditions. The practitioner should inspect the REVOFIL product for uniformity and clarity before proceeding. 

The filler can be administered using either linear threading or bolus techniques, depending on the treatment area and desired outcome. Injection should be performed in the appropriate dermal layer, with the typical dosage being 1ml per session, though this may be adjusted based on patient needs. Initial treatments may require 1–2 sessions, scheduled approximately 4 weeks apart.

Guidelines for Proper Aftercare

• Apply cold compresses after treatment to reduce swelling

• Do not apply makeup for 12 hours post-treatment

• Avoid rubbing or massaging the treated area

• Use gentle skincare products and apply SPF 50 sunscreen

• Avoid heat treatments, intense physical activity, and sun exposure for 48 hours

Duration of Revofil Ultra Effects

• Results typically last up to 12 months
• Duration depends on:
  • Patient’s skin type
  • Type of injection technique used
  • The volume of product injected
  • Severity of wrinkles being treated

Potential Risks and Side Effects

Common side effects:

• Swelling, tenderness, or redness at injection sites

• Mild itching or temporary bruising

• Temporary discomfort post-treatment

Rare complications:

• Hypersensitivity reactions

• Granuloma formation

• Nodule development

• Infection at treatment sites

Revofil Ultra Treatment Contraindications

• Women who are pregnant or breastfeeding

• Patients with allergies to peptides or hyaluronic acid

• Individuals with coagulation disorders or autoimmune diseases

• Patients with severe allergies

• Individuals with unrealistic aesthetic expectations

Treatment should be avoided in:

• Areas with active infections, acne, or inflammation

• Vascular-rich areas

• Cases where other dermal fillers have been mixed

• Situations without proper medical evaluation of patient suitability